EUVIMEDEUVIMED entdecken
Multizentrische StudieKohortenstudieOpen Access · CC BY-NC-ND 4.0

Efficacy and safety of sintilimab and lenvatinib combined with locoregional therapy as first-line treatment in advanced intrahepatic cholangiocarcinoma: a multicenter cohort study

Weixuan Pan, Mingchang Pang, Hu Li, Pengfei Hui, Zijian Leng, Guanhua Yu, Xinyuan Chen, Zhenyu Zhu, Haitao Zhao, Yongchang Zheng

Cancer Immunology, Immunotherapy · 10.08.2026 · 75 (11)

DOI: 10.1007/s00262-026-04517-6 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Cancer Immunology, Immunotherapy, online erschienen am 10.08.2026. Verfasst von Weixuan Pan und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Liver Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, No. 1 Shuaifu…. Hauptthemen laut MEDLINE: Cholangiocarcinoma, Quinolines, Phenylurea Compounds, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Natural Science Foundation of China, Peking Union Medical College Hospital Outstanding Young Talent Development Program.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Chemotherapy, alone or combined with immune checkpoint inhibitors (ICIs), remains the standard first-line treatment for advanced intrahepatic cholangiocarcinoma (ICC), but survival gains are modest. Triple-combination strategies integrating targeted therapy, ICIs, and locoregional treatment have shown promise in biliary tract cancer, yet sintilimab-based regimens have not been systematically evaluated. This study assessed the efficacy and safety of sintilimab plus lenvatinib and locoregional therapy (triple-regimen) in advanced ICC. METHODS: In this multicenter retrospective study, 169 patients with advanced ICC received triple-regimen, ICIs plus chemotherapy (ICIs-chemo), or chemotherapy alone between October 2019 and June 2025. Locoregional modalities included external beam radiation therapy, hepatic arterial infusion chemotherapy, and transarterial chemoembolization. Outcomes included overall survival (OS), progression-free survival (PFS), objective response rate (ORR), disease control rate (DCR), and treatment-related adverse events (AEs). RESULT: The triple-regimen was associated with improved survival versus both comparators. Median PFS was 11.9 months with triple-regimen versus 6.0 months with ICIs-chemo (P < 0.001) and 5.2 months with chemotherapy (P = 0.007); median OS was 18.7 versus 14.4 and 13.4 months (P = 0.044 and 0.036), respectively. ORR was higher with triple-regimen (53.3% vs 25.0% and 28.1%), while DCR was 84.4%, 85.0%, and 73.4%. Grade 3-4 AEs occurred in 62.2%, 60.0%, and 56.3% of patients in the triple-regimen, ICIs-chemo, and chemotherapy groups, respectively; all toxicities were manageable and no treatment-related deaths occurred. CONCLUSIONS: The addition of locoregional treatment to sintilimab and lenvatinib was associated with favorable survival outcomes compared with chemotherapy-based first-line regimens, without a significant increase in the overall incidence of grade 3-4 AEs.This triple-regimen may represent a promising and well-tolerated first-line therapeutic option for patients with advanced ICC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CholangiocarcinomaQuinolinesPhenylurea CompoundsAntineoplastic Combined Chemotherapy ProtocolsBile Duct NeoplasmsHumansFemaleMaleAgedMiddle AgedRetrospective StudiesAdultCombined Modality TherapyAged, 80 and overTreatment OutcomeAntibodies, Monoclonal, Humanized

Stichwörter der Autor:innen

ChemotherapyIntrahepatic cholangiocarcinomaLenvatinibLocoregional therapySintilimab

Substanzen

lenvatinibQuinolinesPhenylurea CompoundssintilimabAntibodies, Monoclonal, Humanized

Autor:innen und Institutionen

  • Department of Liver Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, No. 1 Shuaifuyuan, Beijing, 100730, China.
  • Department of Hepatobiliary Surgery, The Fifth Medical Center of PLA General Hospital, No. 100 West 4th Ring Middle Road, Beijing, 100039, China.
  • Department of Pathology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, No. 1 Shuaifuyuan, Beijing, 100730, China. chenxinyuan_pumc@163.com.
  • Department of Hepatobiliary Surgery, The Fifth Medical Center of PLA General Hospital, No. 100 West 4th Ring Middle Road, Beijing, 100039, China. zhuzy302@163.com.
  • Department of Liver Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, No. 1 Shuaifuyuan, Beijing, 100730, China. zhaoht@pumch.cn.
  • Department of Liver Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, No. 1 Shuaifuyuan, Beijing, 100730, China. zhengyongchang@pumch.cn.

Förderung

  • National Natural Science Foundation of China
  • Peking Union Medical College Hospital Outstanding Young Talent Development Program

Zitieren

APA

Pan, W., Pang, M., Li, H., Hui, P., Leng, Z., Yu, G., Chen, X., Zhu, Z., Zhao, H., & Zheng, Y. (2026). Efficacy and safety of sintilimab and lenvatinib combined with locoregional therapy as first-line treatment in advanced intrahepatic cholangiocarcinoma: a multicenter cohort study. Cancer Immunology, Immunotherapy, 75(11). https://doi.org/10.1007/s00262-026-04517-6

Vancouver

Pan W, Pang M, Li H, Hui P, Leng Z, Yu G, et al. Efficacy and safety of sintilimab and lenvatinib combined with locoregional therapy as first-line treatment in advanced intrahepatic cholangiocarcinoma: a multicenter cohort study. Cancer Immunology, Immunotherapy. 2026;75(11). doi:10.1007/s00262-026-04517-6

BibTeX
@article{Pan2026,
  author = {Pan, Weixuan and Pang, Mingchang and Li, Hu and Hui, Pengfei and Leng, Zijian and Yu, Guanhua and Chen, Xinyuan and Zhu, Zhenyu and Zhao, Haitao and Zheng, Yongchang},
  title = {Efficacy and safety of sintilimab and lenvatinib combined with locoregional therapy as first-line treatment in advanced intrahepatic cholangiocarcinoma: a multicenter cohort study},
  journal = {Cancer Immunology, Immunotherapy},
  year = {2026},
  volume = {75},
  number = {11},
  doi = {10.1007/s00262-026-04517-6}
}
Kostenlos starten →